Cardiol Therapeutics Inc.

A clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease.

Recent News

  • Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

    Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, at 8:40 am EDT.A live audio webcast will be available on the "Events & Presentations" section of Cardiol's website at cardiolrx.com/investors/events-presentations/. A replay of the presentation will be...

    2021-09-16 7:27 AM EDT
  • Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020

    Oakville, Ontario--(Newsfile Corp. - September 10, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces the acceleration of the expiry date of all outstanding common share purchase warrants (the "Warrants") of the Company that were issued on June 4, 2020, pursuant to a Canadian public offering (the "Offering"). The Warrants bear the CUSIP Number: 14161Y127 and the ISIN: CA14161Y1271....

    2021-09-10 4:33 PM EDT
  • Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors

    Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Esq. to its Board of Directors, effective immediately.Michael J. Willner has practiced as both an Attorney and a Certified Public Accountant. He graduated from Emory University Law School as a member of the Emory Law...

    2021-09-07 7:27 AM EDT
  • Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

    Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as...

    2021-08-24 7:27 AM EDT
  • Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"

    Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market LLC ("NASDAQ") to list its common shares on NASDAQ. The Company's shares will begin trading on August 10, 2021, under the symbol "CRDL".The Company's common shares will continue to trade on the Toronto Stock...

    2021-08-09 7:27 AM EDT
  • Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman

    Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that its Board of Directors has appointed Dr. Guillermo Torre-Amione as the new Chairman. Dr. Torre-Amione has been an independent director of Cardiol since August 2018 and is taking over from Dr. Eldon Smith, who is the founding Chairman of Cardiol...

    2021-07-07 7:33 AM EDT
  • Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting

    Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces results from its Annual General and Special Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 29, 2021. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.Resolutions proposed and approved at the...

    2021-06-30 10:03 AM EDT
  • Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT

    Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 29, 2021, at 4:30 p.m. EDT.Cardiol Therapeutics 2021 AGMWhen: June 29, 20214:30 p.m. EDTWhere: Virtual meeting only via live audio...

    2021-06-28 10:03 AM EDT